LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 118

Search options

  1. Article ; Online: Gender in idiopathic pulmonary fibrosis diagnosis: time to address unconscious bias.

    Strek, Mary E

    Thorax

    2020  Volume 75, Issue 5, Page(s) 365–366

    MeSH term(s) Humans ; Idiopathic Pulmonary Fibrosis ; Lung
    Language English
    Publishing date 2020-04-07
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 204353-1
    ISSN 1468-3296 ; 0040-6376
    ISSN (online) 1468-3296
    ISSN 0040-6376
    DOI 10.1136/thoraxjnl-2020-214569
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Occupational Exposures in Rheumatoid Arthritis-related Airway Disease: A Missing Link?

    Lee, Cathryn T / Strek, Mary E

    Annals of the American Thoracic Society

    2022  Volume 19, Issue 6, Page(s) 1076–1077

    MeSH term(s) Arthritis, Rheumatoid/complications ; Humans ; Occupational Exposure/adverse effects ; Respiration Disorders
    Language English
    Publishing date 2022-03-07
    Publishing country United States
    Document type Letter ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 2717461-X
    ISSN 2325-6621 ; 1943-5665 ; 2325-6621
    ISSN (online) 2325-6621 ; 1943-5665
    ISSN 2325-6621
    DOI 10.1513/AnnalsATS.202201-079LE
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Systemic sclerosis-associated interstitial lung disease: Role of the oesophagus in outcomes.

    Strek, Mary E

    Respirology (Carlton, Vic.)

    2018  Volume 23, Issue 10, Page(s) 885–886

    MeSH term(s) Esophagus ; Gastroesophageal Reflux ; Hernia, Hiatal ; Humans ; Lung Diseases, Interstitial ; Scleroderma, Systemic
    Language English
    Publishing date 2018-06-11
    Publishing country Australia
    Document type Editorial ; Comment
    ZDB-ID 1435849-9
    ISSN 1440-1843 ; 1323-7799
    ISSN (online) 1440-1843
    ISSN 1323-7799
    DOI 10.1111/resp.13335
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The other connective tissue disease-associated interstitial lung diseases: Sjogren's syndrome, mixed connective tissue disease, and systemic lupus erythematosus.

    Lee, Cathryn T / Strek, Mary E

    Current opinion in pulmonary medicine

    2021  Volume 27, Issue 5, Page(s) 388–395

    Abstract: Purpose of review: We review the clinical manifestations of three less common connective tissue disease (CTD)-associated interstitial lung diseases (ILDs): Sjogren's syndrome (SjS), mixed CTD (MCTD), and systemic lupus erythematosus (SLE).: Recent ... ...

    Abstract Purpose of review: We review the clinical manifestations of three less common connective tissue disease (CTD)-associated interstitial lung diseases (ILDs): Sjogren's syndrome (SjS), mixed CTD (MCTD), and systemic lupus erythematosus (SLE).
    Recent findings: SjS is classically associated with lymphocytic interstitial pneumonia and cystic lung disease, but the most common type of ILD in Sjogren's patients is nonspecific interstitial pneumonia. ILD is prevalent in MCTD and associated with worse survival. SLE-associated ILD, while rare, is more common in those with CTD overlap syndromes. Regardless of underlying cause, a subset of patients with fibrotic CTD-associated ILD develop a progressive course for which antifibrotic agents and lung transplantation should be considered.
    Summary: An understanding of the characteristics of ILD in SjS, MCTD, and SLE is important for the pulmonary specialist. Future research should identify risk factors for progression and develop additional treatment modalities for both CTD-related autoimmune features and progressive ILD.
    MeSH term(s) Connective Tissue Diseases/complications ; Humans ; Lung Diseases, Interstitial/etiology ; Lupus Erythematosus, Systemic/complications ; Mixed Connective Tissue Disease/complications ; Sjogren's Syndrome/complications
    Language English
    Publishing date 2021-06-14
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 1285505-4
    ISSN 1531-6971 ; 1070-5287 ; 1078-1641
    ISSN (online) 1531-6971
    ISSN 1070-5287 ; 1078-1641
    DOI 10.1097/MCP.0000000000000791
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Implementation of an Interstitial Lung Abnormality Clinic and Multidisciplinary Discussion.

    Selvan, Kavitha / Chelala, Lydia / Lee, Cathryn T / Adegunsoye, Ayodeji / Chung, Jonathan H / Jablonski, Renea / Strek, Mary E

    Respiratory care

    2024  Volume 69, Issue 5, Page(s) 603–607

    Language English
    Publishing date 2024-04-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603252-7
    ISSN 1943-3654 ; 0098-9142 ; 0020-1324
    ISSN (online) 1943-3654
    ISSN 0098-9142 ; 0020-1324
    DOI 10.4187/respcare.11596
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Occupational Burden in Chronic Respiratory Disease: Call for Recognition, Training, and Data Capture.

    Lee, Cathryn T / Strek, Mary E

    American journal of respiratory and critical care medicine

    2019  Volume 200, Issue 12, Page(s) 1558–1559

    MeSH term(s) Humans ; Occupational Health ; Respiration Disorders ; Societies ; United States
    Language English
    Publishing date 2019-07-24
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.201907-1288LE
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis.

    Stahlbaum, Danielle / Jablonski, Renea / Strek, Mary E / Bestvina, Christine M / Polley, Mei-Yin / Reid, Pankti

    Respiratory medicine

    2023  Volume 217, Page(s) 107330

    Abstract: Background: Chronic lung disease is a proposed risk factor for immune checkpoint inhibitor pneumonitis (ICI-pneumonitis); however, data is sparse regarding the impact of pre-existing lung disease and baseline chest imaging abnormalities on the risk of ... ...

    Abstract Background: Chronic lung disease is a proposed risk factor for immune checkpoint inhibitor pneumonitis (ICI-pneumonitis); however, data is sparse regarding the impact of pre-existing lung disease and baseline chest imaging abnormalities on the risk of developing ICI-pneumonitis.
    Methods: We conducted a retrospective cohort study of patients with ICI treatment for cancer from 2015 to 2019. ICI-pneumonitis was determined by the treating physician with corroboration via an independent physician review and exclusion of alternative etiologies. Controls were patients treated with ICI without a diagnosis of ICI-pneumonitis. Fisher's exact tests, Student's t-tests, and logistic regression were used for statistical analysis.
    Results: We analyzed 45 cases of ICI-pneumonitis and 135 controls. Patients with abnormal baseline chest CT imaging (emphysema; bronchiectasis; reticular, ground glass and/or consolidative opacities) had increased risk for ICI-pneumonitis (OR 3.41, 95%CI: 1.68-6.87, p = 0.001). Patients with gastroesophageal reflux disease (GERD) (OR 3.83, 95%CI: 1.90-7.70, p = < 0.0001) also had increased risk for ICI-pneumonitis. On multivariable logistic regression, patients with abnormal baseline chest imaging and/or GERD remained at increased risk for ICI-pneumonitis. Eighteen percent of all patients (32/180) had abnormal baseline chest CT consistent with chronic lung disease without a documented diagnosis.
    Conclusion: Patients with baseline chest CT abnormalities and GERD were at increased risk for developing ICI-pneumonitis. The large proportion of patients with baseline radiographic abnormalities without a clinical diagnosis of chronic lung disease highlights the importance of multidisciplinary evaluation prior to ICI initiation.
    Language English
    Publishing date 2023-06-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 1003348-8
    ISSN 1532-3064 ; 0954-6111
    ISSN (online) 1532-3064
    ISSN 0954-6111
    DOI 10.1016/j.rmed.2023.107330
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Recent Advances in Severe Asthma: From Phenotypes to Personalized Medicine.

    Schoettler, Nathan / Strek, Mary E

    Chest

    2019  Volume 157, Issue 3, Page(s) 516–528

    Abstract: This review focuses on recent clinical and translational discoveries in severe and uncontrolled asthma that now enable phenotyping and personalized therapies in these patients. Although asthma is common in both children and adults and typically responds ... ...

    Abstract This review focuses on recent clinical and translational discoveries in severe and uncontrolled asthma that now enable phenotyping and personalized therapies in these patients. Although asthma is common in both children and adults and typically responds to standard therapies, a subset of individuals with asthma experience severe and/or persistent symptoms despite appropriate therapies. Airflow obstruction leading to frequent symptoms requiring higher levels of controller therapy is the cardinal feature of severe asthma, but the underlying molecular mechanisms, or endotypes, are diverse and variable between individuals. Two major risk factors that contribute to severe asthma are genetics and environmental exposures that modulate immune responses, and although these often interact in complex manners that are not fully understood, certain endotypes converge in severe asthma. A number of studies have evaluated various features of patients with severe asthma and classified patients into phenotypes with clinical relevance. This phenotyping is now incorporated into clinical practice and can be used to guide advanced biological therapies that target specific molecules and inflammatory pathways that contribute to asthma pathogenesis.
    MeSH term(s) Anti-Asthmatic Agents/therapeutic use ; Asthma/classification ; Asthma/diagnosis ; Asthma/physiopathology ; Asthma/therapy ; Biological Products/therapeutic use ; Bronchial Thermoplasty ; Environmental Exposure ; Genetic Predisposition to Disease ; Humans ; Phenotype ; Precision Medicine ; Risk Factors ; Severity of Illness Index
    Chemical Substances Anti-Asthmatic Agents ; Biological Products
    Language English
    Publishing date 2019-10-31
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 1032552-9
    ISSN 1931-3543 ; 0012-3692
    ISSN (online) 1931-3543
    ISSN 0012-3692
    DOI 10.1016/j.chest.2019.10.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.

    Maher, Toby M / Strek, Mary E

    Respiratory research

    2019  Volume 20, Issue 1, Page(s) 205

    Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced vital capacity (FVC) in patients with IPF appears to be almost linear, ...

    Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced vital capacity (FVC) in patients with IPF appears to be almost linear, with patients with well-preserved FVC at baseline experiencing the same rate of decline in FVC as patients with more advanced disease. Two antifibrotic therapies have been approved for the treatment of IPF: nintedanib and pirfenidone. These drugs slow decline in lung function and reduce the risk of acute respiratory deteriorations, which are associated with very high morbidity and mortality. Individual clinical trials have not been powered to show reductions in mortality, but analyses of pooled data from clinical trials, as well as observational studies, suggest that antifibrotic therapies improve life expectancy. Despite this, many individuals with IPF remain untreated. In many cases, this is because the physician perceives that the disease is stable and so does not warrant therapy, or has concerns over the potential side-effects of antifibrotic drugs. There remains a need to educate pulmonologists that IPF is a progressive, irreversible and fatal disease and that prompt treatment is critical to preserving patients' lung function and improving outcomes. Most individuals can tolerate antifibrotic therapy, and dose adjustment has been shown to be effective at reducing side effects without compromising efficacy. In addition to anti-fibrotic therapies, individuals with IPF benefit from a holistic approach to their care that includes symptom management and supportive care tailored to the needs of the individual. An animation illustrating the themes covered in this article will be available at: http://www.usscicomms.com/respiratory/maher/treatment-of-IPF .
    MeSH term(s) Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Clinical Trials as Topic/methods ; Humans ; Idiopathic Pulmonary Fibrosis/diagnosis ; Idiopathic Pulmonary Fibrosis/drug therapy ; Idiopathic Pulmonary Fibrosis/metabolism ; Indoles/administration & dosage ; Protein Kinase Inhibitors/administration & dosage ; Pyridones/administration & dosage ; Time-to-Treatment/standards
    Chemical Substances Anti-Inflammatory Agents, Non-Steroidal ; Indoles ; Protein Kinase Inhibitors ; Pyridones ; pirfenidone (D7NLD2JX7U) ; nintedanib (G6HRD2P839)
    Language English
    Publishing date 2019-09-06
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2041675-1
    ISSN 1465-993X ; 1465-9921
    ISSN (online) 1465-993X
    ISSN 1465-9921
    DOI 10.1186/s12931-019-1161-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Pulmonary Alveolar Proteinosis-associated Pulmonary Fibrosis: Evolutional Changes and Radiologic-Pathologic Correlation.

    Hu-Wang, Eileen / Chelala, Lydia / Landeras, Luis / Li, Huihua / Husain, Aliya N / Strek, Mary E / Chung, Jonathan H

    Radiology. Cardiothoracic imaging

    2023  Volume 5, Issue 5, Page(s) e230040

    Abstract: Pulmonary alveolar proteinosis (PAP) is a rare disease with frequently favorable outcomes. In a minority of patients with primary or secondary PAP, the disease course may be complicated by pulmonary fibrosis (PF) despite appropriate management. Imaging ... ...

    Abstract Pulmonary alveolar proteinosis (PAP) is a rare disease with frequently favorable outcomes. In a minority of patients with primary or secondary PAP, the disease course may be complicated by pulmonary fibrosis (PF) despite appropriate management. Imaging and histopathologic manifestations of uncomplicated PAP are well-known. In contrast, radiologic-pathologic descriptions of PAP-associated PF (PAP-PF) are limited. The current manuscript presents three cases of PAP-PF, each with serial high-resolution CT imaging demonstrating the longitudinal progression of this unusual complication, with concordant pathologic findings in two patients. Much remains to be known regarding adverse prognostic factors contributing to PAP-PF. Early recognition of radiologic-pathologic manifestations would allow timely diagnosis and management optimization.
    Language English
    Publishing date 2023-10-19
    Publishing country United States
    Document type Case Reports
    ISSN 2638-6135
    ISSN (online) 2638-6135
    DOI 10.1148/ryct.230040
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top